BioSpace News Archive

Dantari, Inc., a clinical-stage biotechnology company developing best-in-class targeted therapeutics for the treatment of cancers and other diseases, announced its emergence from stealth mode with $47 million Series A financing.

RAPT Therapeutics, Inc. (Nasdaq: RAPT) today reported a poster presentation at the ESMO IO Congress covering data from its ongoing Phase 1/2 clinical trial of FLX475 as monotherapy and in combination with pembrolizumab in patients with advanced cancer (NCT03674567).

Be Biopharma (“Be Bio”) today announced the appointment of John Mayfield, Ph.D., to the newly created position of Chief Business Officer.

Takeda today announced that the European Commission (EC) granted marketing authorization for the company’s dengue vaccine QDENGA ® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) for the prevention of dengue disease in individuals from four years of age in the European Union (EU).i QDENGA should be used in accordance with official recommendations.

KalVista Pharmaceuticals, Inc. today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2022.

BD (Becton, Dickinson and Company) today announced the release of its second annual Global Inclusion, Diversity and Equity Report for fiscal year 2022.

XORTX Therapeutics Inc. is pleased to announce new proof of concept data demonstrating, in a second study, the effectiveness of xanthine oxidase inhibition (“XOI”) produced by the Company’s proprietary oral oxypurinol formulation, XORLO TM.

BIOXYTRAN, INC. announced the receipt of an Investigational New Drug (IND) authorization letter from India’s Central Drugs Standard Control Organization (CDSCO) to optimize dosage in Covid-19 patients.

Currently circulating mutant strains of influenza highlight the need for multi-target diagnostic tests.

Numinus Wellness Inc. today announced that its research division has submitted a clinical trial application to Health Canada to begin a new experiential training study that will enable practitioners training to provide Psilocybin-Assisted Therapy (PAT) the ability to experience and observe psilocybin sessions to further their understanding and PAT education.